Recently, we demonstrated that the expression of SLC7A11, which encodes the functional subunit of the cystine-glutamate antiporter, system xc−, is a superior determinant of response to eprenetapopt across cancer lineages, surpassing both TP53 mutation status and p53 protein levels (6). This evidence concerns the gene SLC7A11 and cancer.